title: Natalizumab to fingolimod: Questions answered, unanswered, and unasked.
authors.affiliation: From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR. olaf.stuve@utsouthwestern.edu.
authors.forename: Olaf
authors.initials: O
authors.lastname: Stüve
authors.affiliation: From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR.
authors.forename: Dennis
authors.initials: D
authors.lastname: Bourdette
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D057915:Drug Substitution; D006801:Humans; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011409:Propylene Glycols / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D013110:Sphingosine / Q000031:analogs & derivatives*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D011409:Propylene Glycols; D013110:Sphingosine